Tapewire

Nasdaq · USD

VRXA

Veraxa Biotech AG - Post de-SPAC

Export transactions ↓
Tapewire entity
6310
SEC CIK
0002079109
Parsed reports
11

Last 12 months

Inside the activity.

2 purchase rows · 0 sale rows

Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.
Monthly counts
MonthPurchasesSales
Nov 202500
Dec 202500
Jan 202600
Feb 202600
Mar 202600
Apr 202600
May 202600
Jun 202600
Jul 202600
Aug 202620
Sep 202600
Oct 202600

Latest available

Insider transactions

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateOwner / reported roleActivity / securityShares / unitsReported priceReported valueDetails
August 27, 2026 Filed Aug 31, 2026 20:10 UTC PurchaseOrdinary Shares 50,000 $1.50 $75,000.00
Disclosure

SEC source: 0001829126-26-009544 · ownership.xml · nonDerivative · entry 1

Baumann Oliver Rolf · CIK 0002129436 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 5,773,618

F1 · ownership.direct: The reported securities are held by Akira Holding AG. The reporting person may be deemed to beneficially own such securities by virtue of their relationship with Akira Holding AG.

F1 · ownership.nature: The reported securities are held by Akira Holding AG. The reporting person may be deemed to beneficially own such securities by virtue of their relationship with Akira Holding AG.

Read SEC document
August 27, 2026 Filed Aug 31, 2026 20:10 UTC
Antz Christoph RudigerDirector · Chief Executive Officer
PurchaseOrdinary Shares 5,000 $1.53 $7,650.00
Disclosure

SEC source: 0001829126-26-009543 · ownership.xml · nonDerivative · entry 1

Antz Christoph Rudiger · CIK 0002123284 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,000

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.